Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 9/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2712652 | 0.85 | KDM1A (0.44) | RORCMAPTKDM1A | |
| SCHEMBL13201877 | 0.81 | GPR119 (0.44) | RORCJAK1KDM1AGPR119 | |
| SCHEMBL8246876 | 0.81 | GPR119 (0.44) | RORCJAK1KDM1AGPR119 | |
| SCHEMBL13219044 | 0.80 | RORC (0.44) | RORCJAK1KDM1AGPR119 | |
| SCHEMBL13201885 | 0.80 | RORC (0.44) | RORCJAK1KDM1AGPR119 | |
| SCHEMBL8247420 | 0.80 | RORC (0.42) | RORCJAK1KDM1AGPR119 | |
| SCHEMBL2727269 | 0.79 | GPR119 (0.55) | RORCJAK2MAPTGPR119 | |
| SCHEMBL23752795 | 0.78 | MGLL (0.54) | RORC | |
| SCHEMBL5242538 | 0.78 | RORC (0.57) | RORC | |
| SCHEMBL4629158 | 0.78 | RORC (0.44) | RORCJAK1KDM1AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015051766-A1 | AMIDS SUBSTITUTED INDAZOLE DERIVATIVEES AS PLOY (ADP-RIBOSE) POLYMERASE INHIBITORS | BETTA PHARMACEUTICALS CO., LTD (CN) | 2015-04-16 | — | — | WO | disclosed |
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
| EP-2445887-A2 | NOVEL AZABICYCLOHEXANES | Panacea Biotec Limited (IN) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010150281-A2 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | ACHE 1759/4885RORC 113/4885KEAP1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.